1. Characteristic 1: use a formula compound (1) or its salt or pharmaceutically acceptable ester； each R1 is h or halogen； each R2 is halogen； each R3 or R5 is independent h, ora, n (RA) 2, N3, CN, NO2, s (or) NRA, halogen, c1-8 tar, carbocylalquillo c4-8, c1-8 substitute, alquenilo C2-8, alquenio C2-8 alternative, C2-8 tar or C2-8 alternative, R6 is h, ora, n (RA) 2, N3, CN, NO2, s (o) nra-c (= O) R11, = C (= O) nr11r12, = C (= O) sr11, - S (o) R11, - S (o) 2r11, - S (o) (or11),-S (O) 2 (OR11)-SO2NR11R12 hal geno alquilo C1-8 carbociclilalquilo C4-8 alquilo C1-8 sustituido alquenilo C2-8 alquenilo C2-8 sustituido alquinilo C2-8 alquinilo C2-8 sustituido o arilalquilo C1-8 cada n es de manera independiente 0 1 2 cada -S (O) 2 (OR11)or -SO2NR11R12； R7 is H, -C (= O) R11, -C (= O) OR11, -C (= O) NR11R12, -C (= O) SR11, -S (O) R11, -S (O) 2R11, -S (O) (OR11),-S (O) 2 (OR11)-So2nr11r12 or one of the other formulas (2)；Each and Y1 are independent o, s, NR, + n (o) (R),No, No.2BN (O) (OR)O n-nr2； W1 and W2, together, are - Y3 (C (ry) 2) 3y3 -；Or one W1 or W2 plus R3 is - Y3, the other W1 or W2 plus formula (3)；W1 and W2 are a set of formula (3), respectively,Each Y2 is a separate alliance, O, CR2, NR, + n (o) (R),No, No.2BN (O) (OR)N-NR2 S S-S S (O)o S (O) 2 cada Y3 es de manera independiente OS o NR M2 es 0 1 2 cada Rx es de manera independiente Ry o la f rmula (4) donde cada M1a M1c y M1d es de manera independiente 0 1 M12c es 0 1 -S (O) 2 (OR)-OC (3DY1) R -OC (3DY1) OR -OC (3DY1) (N (R) 2)-SC (3DY1) R -SC (3DY1) OR -SC (3DY1) (N (R) 2)-N (R) C (= Y1) R, -N (R) C (= Y1) OR, -N (R) C (= Y1) N (R) 2, -SO2NR2, -CN, -N3, - NO2, -OR, or W3； or when taken together, two Ry's on the same carbon atom form a carbocyclic ring of between 3 and 7 carbon atoms； each R is independently H, C1-8 alkyl, substituted C1-8 alkyl, C2-8 alkenyl, substituted C2-8 alkenyl, C2-8 alkynyl, C2-8 substituted alkynyl, C6-20 aryl, C6 aryl -20 substituted, C2-20 heterocyclyl, substituted C2-20 heterocy
